Scientists test Triple-Threat attack on Tough-to-Treat breast cancer
NCT ID NCT04253561
Summary
This early-stage study tested adding a new drug called ipatasertib to two standard medications (trastuzumab and pertuzumab) for people with advanced HER2-positive breast cancer that also has a specific genetic change (PIK3CA mutation). The main goal was to find the safest and most effective dose of the new three-drug combination and to see how well patients tolerated it, with a special focus on managing side effects like diarrhea. It involved 17 patients whose cancer had spread and who had already received initial treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Centro Integral Oncológico Clara Campal (CIOCC)
Madrid, Madrid, Spain
-
Comp. Hosp.Univ. Santiago (Chus)
Santiago de Compostela, La Coruña, Spain
-
Fundación Instituto Valenciano de Oncología
Valencia, Valencia, Spain
-
H.Univ. Arnau de Vilanova de Lleida
Lleida, Lleida, Spain
-
Hospital Universitario Doce de Octubre
Madrid, Madrid, Spain
-
Hospital Universitario Virgen del Rocio
Seville, Sevilla, Spain
-
Hospital Universitario del Vall d' Hebron
Barcelona, Barcelona, Spain
-
Hospital Virgen de Macarena
Seville, Sevilla, Spain
-
ICO Badalona
Badalona, Barcelona, Spain
-
MD Anderson
Madrid, Madrid, Spain
Conditions
Explore the condition pages connected to this study.